Publication: Malignancy risk in systemic lupus erythematosus patients treated with cyclophosphamide
dc.contributor.author | Yilmaz, N. | |
dc.contributor.author | Emmungil, H. | |
dc.contributor.author | Gücenmez, S. | |
dc.contributor.author | Özen, G. | |
dc.contributor.author | Yıldız, F. | |
dc.contributor.author | Balkarlı, A. | |
dc.contributor.author | Kimyon, G. | |
dc.contributor.author | Coşkun, B. Necdet | |
dc.contributor.author | Doğan, I. | |
dc.contributor.author | Pamuk, O. N. | |
dc.contributor.author | Yaşar, S. | |
dc.contributor.author | Cetin, G. Yildirim | |
dc.contributor.author | Yazıcı, A. | |
dc.contributor.author | Esmen, S. Ergülü | |
dc.contributor.author | Cağatay, Y. | |
dc.contributor.author | Yılmaz, S. | |
dc.contributor.author | Celle, A. | |
dc.contributor.author | Cefle, A. | |
dc.contributor.author | Sayarhoğlu, M. | |
dc.contributor.author | Kaşifoğlu, T. | |
dc.contributor.author | Karadağ, O. | |
dc.contributor.author | Pehlivan, Yavuz | |
dc.contributor.author | Dalkılıç, Ediz | |
dc.contributor.author | Kısacık, B. | |
dc.contributor.author | Cobankara, V. | |
dc.contributor.author | Erken, E. | |
dc.contributor.author | Direskeneli, H. | |
dc.contributor.author | Aksu, K. | |
dc.contributor.author | Yavuz, S. | |
dc.contributor.buuauthor | COŞKUN, NEJDET | |
dc.contributor.buuauthor | PEHLİVAN, YAVUZ | |
dc.contributor.buuauthor | DALKILIÇ, HÜSEYİN EDİZ | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Bölümü | |
dc.contributor.orcid | 0000-0003-0298-4157 | |
dc.contributor.researcherid | ETE-5180-2022 | |
dc.contributor.researcherid | AAG-8227-2021 | |
dc.contributor.researcherid | AAG-7155-2021 | |
dc.date.accessioned | 2024-08-12T06:16:53Z | |
dc.date.available | 2024-08-12T06:16:53Z | |
dc.date.issued | 2015-05-01 | |
dc.description | Bu çalışma, 02-06, Eylül 2015 tarihlerinde Vienna[Avusturya]’da düzenlenen 11. International Congress on Systemic Lupus Erythematosus Kongresi‘nde bildiri olarak sunulmuştur. | |
dc.identifier.endpage | S67 | |
dc.identifier.issn | 0392-856X | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | S67 | |
dc.identifier.uri | https://hdl.handle.net/11452/43882 | |
dc.identifier.volume | 33 | |
dc.identifier.wos | 000360421900240 | |
dc.indexed.wos | WOS.SCI | |
dc.indexed.wos | WOS.ISTP | |
dc.language.iso | en | |
dc.publisher | Clinical & Exper Rheumatology | |
dc.relation.journal | Clinical and Experimental Rheumatology | |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Rheumatology | |
dc.subject | Rheumatology | |
dc.title | Malignancy risk in systemic lupus erythematosus patients treated with cyclophosphamide | |
dc.type | Meeting Abstract | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 0041a709-5005-4d5d-951f-94e7d0932f3b | |
relation.isAuthorOfPublication | 0075f2ae-ae8a-4690-bd46-128775e8efac | |
relation.isAuthorOfPublication | 1613225c-2f43-4052-9f82-210c854edcf4 | |
relation.isAuthorOfPublication.latestForDiscovery | 0041a709-5005-4d5d-951f-94e7d0932f3b |